UCB SA (OTCMKTS:UCBJF) Stock Rated “Moderate Buy” by Sell-Side Analysts

UCB SA (OTCMKTS:UCBJF) has earned a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and five have issued a buy rating on the company.

A number of brokerages have issued reports on UCBJF. Jefferies Financial Group raised UCB to a “hold” rating in a report on Monday, August 3rd. Piper Sandler restated a “neutral” rating on shares of UCB in a research report on Wednesday, July 22nd. Finally, Stephens reaffirmed an “overweight” rating on shares of UCB in a report on Wednesday, October 21st.

UCB Trading Up 0.4%

Shares of UCBJF stock opened at $314.92 on Friday. UCB has a 52-week low of $219.60 and a 52-week high of $345.39. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The business has a 50-day simple moving average of $256.20 and a 200-day simple moving average of $285.90.

About UCB

UCB is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for people living with severe diseases. Its primary therapeutic areas are neurology and immunology, with research activities spanning conditions such as epilepsy, myasthenia gravis, Parkinson’s disease, psoriasis, psoriatic arthritis, axial spondyloarthritis and other immune-mediated disorders.

The company’s medicines include Bimzelx (bimekizumab), an immunology treatment; Cimzia (certolizumab pegol), used for several inflammatory conditions; and a portfolio of neurological therapies that includes Briviact (brivaracetam), Keppra (levetiracetam), Fintepla (fenfluramine) and Nayzilam (midazolam).